Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats

AIMS/INTRODUCTION: Type 2 diabetes mellitus is a risk factor of acute kidney injury after myocardial infarction (MI), a form of cardiorenal syndrome. Recent clinical trials have shown that a sodium–glucose cotransporter 2 (SGLT2) inhibitor improved both cardiac and renal outcomes in patients with ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Yukishige, Kuno, Atsushi, Tanno, Masaya, Sato, Tatsuya, Ohno, Kouhei, Shibata, Satoru, Nakata, Kei, Sugawara, Hirohito, Abe, Koki, Igaki, Yusuke, Yano, Toshiyuki, Miki, Takayuki, Miura, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626958/
https://www.ncbi.nlm.nih.gov/pubmed/30663266
http://dx.doi.org/10.1111/jdi.13009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626958/
https://www.ncbi.nlm.nih.gov/pubmed/30663266
http://dx.doi.org/10.1111/jdi.13009

Ejemplares similares